GOVX : Summary for GEOVAX LABS INC COM STK USD0.01 - Yahoo Finance

U.S. Markets closed

GeoVax Labs, Inc. (GOVX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.07+0.00 (+2.30%)
At close: 2:40PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.07
Bid0.00 x
Ask0.00 x
Day's Range0.07 - 0.07
52 Week Range0.05 - 0.14
Avg. Volume239,177
Market Cap3.31M
PE Ratio (TTM)-0.81
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marketwired5 days ago

    GeoVax to Collaborate with Georgia State University on Development of Therapeutic Hepatitis B Vaccine

    GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today that it has entered into a research collaboration agreement with Georgia State University Research Foundation to advance ...

  • Marketwired13 days ago

    GeoVax and Burnet Institute to Join Forces to Develop Malaria Vaccine

    GeoVax Labs, Inc. announced today that it has entered into a research collaboration agreement with the Burnet Institute, a leading infectious diseases research institute in Australia, for the development ...

  • American City Business Journals17 days ago

    Zika vaccine developer names new chief scientific officer

    A Smyrna-based developer of vaccines against Zika, Ebola, HIV and other infectious diseases has named a new chief scientific officer. Farshad Guirakhoo was promoted to the C-suite role at GeoVax Labs Inc. from senior vice president of research and development, his title upon joining the company in 2015. "For the past year, Farshad has been a driving force behind the growth of our vaccine development pipeline, and we are pleased to expand his role at this critical time for our company," GeoVax President and CEO Robert T. McNally said in the statement.